Answers are grounded in this paper and cite their sources.
The selective adenosine A2A receptor agonists 2-[p-(2-carboxethyl)phenylethylaminol-5′-N-ethylcarboxyamidoadenosine (CGS 21680), N-[2-(3,5-dimethoxyphenyl)ethyl]adenosine (DPMA) and metrifudil were investigated for their ability to prevent the loss of pyramidal CA1 neurons in the hippocampus following 5 min of severe temporary forebrain ischemia in mongolian gerbils. CGS 21680, when administered at 18.7 μmol/kg 30 and 120 min following reperfusion, exhibited highly significant protection against neuronal loss, but was inactive at 5.6 μmol/kg. DPMA, a more potent agonist at A1 and A2A receptors, was inactive up to a dose of 19 μmol/kg. Metrifudil (equipotent with CGS 21680 at A2A >25 times more potent at A1) gave a modest degree of protection at 26 μmol/kg and was inactive at 7.8 μmol/kg. CGS 21680 showed an equal degree of hypothermia at 5.6 and 18.7 μmol/kg, suggesting that this was not the prime mode of action. While the effect of metrifudil may be the result of its higher A1 receptor affinity, the mode of action of CGS 21680 has not been established; the data, however, suggest that a non-A1 non-A2A receptor mechanism may possibly be involved. Drug Dev. Res. 39:108–114 © 1997 Wiley-Liss, Inc.
No takes yet. Share an insight, caveat, or question.
Sheardown et al. (1996) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: